SEC Form 4 · accession 0000899243-17-000805
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jose Baselga
Director
Period of report
Jan 6, 2017
Accepted (ET)
Jan 9, 2017 · 4:47 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.46 | Jan 6, 2017 | A | 40,000 | A | — | Jan 6, 2027 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The option vests as to 1/8th of the shares on March 31, 2017 and as to 1/8th of the shares at the end of each calendar quarter thereafter, provided that the holder continues to serve as a director of the issuer.